Research programme: urokinase inhibitors - Molecumetics
Latest Information Update: 04 Sep 2000
At a glance
- Originator Molecumetics
- Class Small molecules
- Mechanism of Action Urokinase-type plasminogen activator inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Sep 2000 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 17 Nov 1998 New profile
- 17 Nov 1998 Preclinical development for Cancer in USA (Unknown route)